Doxorubicin cardiotoxicity in the rat: An in vivo characterization

Journal of the American Association for Laboratory Animal Science

Volumn 46, Issue 4, 2007, Pages 20-32

  Hayward, Reid ^a   Hydock, David S ^a  

^a UNIVERSITY OF NORTHERN COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ANTINEOPLASTIC ANTIBIOTIC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CONTROLLED STUDY; FLOW RATE; HEART FUNCTION; IN VIVO STUDY; MALE; MORTALITY; NONHUMAN; RAT; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; SURVIVAL; TRANSTHORACIC ECHOCARDIOGRAPHY; ANIMAL; BLOOD PRESSURE; BODY SIZE; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ECHOCARDIOGRAPHY; ECHOGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION;

RATTUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOOD PRESSURE; BODY SIZE; CARDIOVASCULAR DISEASES; DOXORUBICIN; ECHOCARDIOGRAPHY; INJECTIONS, INTRAPERITONEAL; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 36048978125     PISSN: 15596109     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Agarwala S, Kumar R, Bhatnagar V, Bajpai M, Gupta DK, Mitra DK. 2000. High incidence of adriamycin cardiotoxicity in children even at low cumulative doses: role of radionuclide cardiac angiography. J Pediatr Surg 35:1786-1789.
2. Ahn J, Varagic J, Slama M, Susic D, Frohlich ED. 2004. Cardiac structural and functional responses to salt loading in SHR. Am J Physiol Heart Circ Physiol 287:H767-772.
3. Ascensao A, Magalhaes J, Soares JM, Ferreira R, Neuparth MJ, Marques F, Oliveira PJ, Duarte JA. 2005. Moderate endurance training prevents doxorubicin-induced in vivo mitochondriopathy and reduces the development of cardiac apoptosis. Am J Physiol Heart Circ Physiol 289:H722-731.
4. Berrak SG, Ewer MS, Jaffe N, Pearson P, Ried H, Zietz HA, Benjamin RS. 2001. Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules. Oncol Rep 8:611-614.
5. Bontenbal M, Andersson M, Wildiers J, Cocconi G, Jassem J, Paridaens R, Rotmensz N, Sylvester R, Mouridsen HT, Klijn JG, van Oosterom AT. 1998. Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group. Br J Cancer 77:2257-2263.
6. Chicco AJ, Hydock DS, Schneider CM, Hayward R. 2006. Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity. J Appl Physiol 100:519-527.
7. Chicco AJ, Schneider CM, Hayward R. 2006. Exercise training attenuates acute doxorubicin-induced cardiac dysfunction. J Cardiovasc Pharmacol 47:182-189.
8. Christie J, Sheldahl LM, Tristani FE, Sagar KB, Ptacin MJ, Wann S. 1987. Determination of stroke volume and cardiac output during exercise: comparison of two-dimensional and Doppler echocardiography, Fick oximetry, and thermodilution. Circulation 76:539-547.
9. Chua CC, Liu X, Gao J, Hamdy RC, Chua BH. 2006. Multiple actions of pifithrin-alpha on doxorubicin-induced apoptosis in rat myoblastic H9c2 cells. Am J Physiol Heart Circ Physiol 290: H2606-2613.
10. Cigremis Y, Parlakpinar H, Polat A, Colak C, Ozturk F, Sahna E, Ermis N, Acet A. 2006. Beneficial role of aminoguanidine on acute cardiomyopathy related to doxorubicin-treatment. Mol Cell Biochem 285:149-154.
11. Cusack BJ, Gambliel H, Musser B, Hadjokas N, Shadle SE, Charlier H, Olson RD. 2006. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism. Cancer Chemother Pharmacol 58:517-526.
12. de Beer EL, Bottone AE, van Rijk MC, van der Velden J, Voest EE. 2002. Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics. Br J Pharmacol 135:1707-1714.
13. Durak I, Karaayvaz M, Kavutcu M, Cimen MY, Kacmaz M, Buyukkocak S, Ozturk HS. 2000. Reduced antioxidant defense capacity in myocardial tissue from guinea pigs treated with 5-fluorouracil. J Toxicol Environ Health A 59:585-589.
14. Elbl L, Vasova I, Kral Z, Tomaskova I, Smardova L, Wagnerova B, Jedlicka F, Vorlicek J. 2006. Evaluation of acute and early cardiotoxicity in survivors of Hodgkin's disease treated with ABVD or BEACOPP regimens. J Chemother 18:199-208.
15. Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC. 2005. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111:1601-1610.
16. Gianni L, Dombernowsky P, Sledge G, Martin M, Amadori D, Arbuck SG, Ravdin P, Brown M, Messina M, Tuck D, Weil C, Winograd B. 2001. Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer. Ann Oncol 12:1067-1073.
17. Gorodetskaya EA, Dugin SF, Golikov MA, Kapelko VI, Medvedev OS. 1990. The cardiac contractile function and hemodynamic control in rats after chronic adriamycin treatment. Can J Physiol Pharmacol 68:211-215.
18. Jegger D, Jeanrenaud X, Nasratullah M, Chassot PG, Mallik A, Tevaearai H, von Segesser LK, Segers P, Stergiopulos N. 2006. Noninvasive Doppler-derived myocardial performance index in rats with myocardial infarction: validation and correlation by conductance catheter. Am J Physiol Heart Circ Physiol 290: H1540-1548.
19. Jensen RA, Acton EM, Peters JH. 1984. Doxorubicin cardiotoxicity in the rat: comparison of electrocardiogram, transmembrane potential, and structural effects. J Cardiovasc Pharmacol 6:186-200.
20. Kim C, Kim N, Joo H, Youm JB, Park WS, Cuong DV, Park YS, Kim E, Min CK, Han J. 2005. Modulation by melatonin of the cardiotoxic and antitumor activities of adriamycin. J Cardiovasc Pharmacol 46:200-210.
21. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, Freireich EJ. 1982. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96:133-139.
22. Legha SS, Benjamin RS, Mackay B, Yap HY, Wallace S, Ewer M, Blumenschein GR, Freireich EJ. 1982. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer 49:1762-1766.
23. Li K, Sung RY, Huang WZ, Yang M, Pong NH, Lee SM, Chan WY, Zhao H, To MY, Fok TF, Li CK, Wong YO, Ng PC. 2006. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 113:2211-2220.
24. Li T, Danelisen I, Bello-Klein A, Singal PK. 2000. Effects of probucol on changes of antioxidant enzymes in adriamycin- induced cardiomyopathy in rats. Cardiovasc Res 46:523-530.
25. Libonati JR, Gaughan JP. 2006. Low-intensity exercise training improves survival in Dahl salt hypertension. Med Sci Sports Exerc 38:856-858.
26. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. 1991. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808-815.
27. Matsui H, Morishima I, Numaguchi Y, Toki Y, Okumura K, Hayakawa T. 1999. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci 65:1265-1274.
28. Menegola E, Broccia ML, Di RF. 2002. Histological study of timing and embryology of notochordal abnormalities in rat exposed in utero to Doxorubicin. Histol Histopathol 17:31-38.
29. Mohamed HE, El-Swefy SE, Hagar HH. 2000. The protective effect of glutathione administration on adriamycin-induced acute cardiac toxicity in rats. Pharmacol Res 42:115-121.
30. Mohan IK, Kumar KV, Naidu MU, Khan M, Sundaram C. 2006. Protective effect of CardiPro against doxorubicin-induced cardiotoxicity in mice. Phytomedicine 13:222-229.
31. Monnet E, Orton EC. 1999. A canine model of heart failure by intracoronary adriamycin injection: hemodynamic and energetic results. J Card Fail 5:255-264.
32. Nakamura T, Ueda Y, Juan Y, Katsuda S, Takahashi H, Koh E. 2000. Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: in vivo study. Circulation 102:572-578.
33. National Research Council. 1996. Guide for the care and use of laboratory animals. Washington(DC): National Academy Press.
34. Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. 2002. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer 86:1697-1700.
35. Oz E, Erbas D, Surucu HS, Duzgun E. 2006. Prevention of doxorubicin-induced cardiotoxicity by melatonin. Mol Cell Biochem 282:31-37.
36. Oz E, Ilhan MN. 2006. Effects of melatonin in reducing the toxic effects of doxorubicin. Mol Cell Biochem 286:11-15.
37. Rabelo E, De Angelis K, Bock P, Gatelli Fernandes T, Cervo F, Bello Klein A, Clausell N, Claudia Irigoyen M. 2001. Baroreflex sensitivity and oxidative stress in adriamycin-induced heart failure. Hypertension 38:576-580.
38. Saad SY, Najjar TA, Al-Rikabi AC. 2001. The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res 43:211-218.
39. Sacco G, Giampietro R, Salvatorelli E, Menna P, Bertani N, Graiani G, Animati F, Goso C, Maggi CA, Manzini S, Minotti G. 2003. Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity. Br J Pharmacol 139:641-651.
40. Sahna E, Parlakpinar H, Ozer MK, Ozturk F, Ozugurlu F, Acet A. 2003. Melatonin protects against myocardial doxorubicin toxicity in rats: role of physiological concentrations. J Pineal Res 35:257-261.
41. Shah HR, Vaynblat M, Salciccioli L, Impellizzeri P, Cunningham JN, Jr, Chiavarelli M. 2000. Composite cardiac binding in experimental heart failure. Ann Thorac Surg 69:429-434.
42. Siveski-Iliskovic N, Hill M, Chow DA, Singal PK. 1995. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 91:10-15.
43. Siveski-Iliskovic N, Kaul N, Singal PK. 1994. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 89:2829-2835.
44. Suzuki K, Murtuza B, Suzuki N, Smolenski RT, Yacoub MH. 2001. Intracoronary infusion of skeletal myoblasts improves cardiac function in doxorubicin-induced heart failure. Circulation 104: 1213-217.
45. Swain SM, Whaley FS, Ewer MS. 2003. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869-2879.
46. Tamura T, Said S, Harris J, Lu W, Gerdes AM. 2000. Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-angiotensin system. Circulation 102:253-259.
47. Tei C, Nishimura RA, Seward JB, Tajik AJ. 1997. Noninvasive Doppler-derived myocardial performance index: correlation with simultaneous measurements of cardiac catheterization measurements. J Am Soc Echocardiogr 10:169-178.
48. Teraoka K, Hirano M, Yamaguchi K, Yamashina A. 2000. Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats. Eur J Heart Fail 2:373-378.
49. Thomas L, Bellmont S, Christen MO, La Roche B, Monassier L. 2004. Cardiovascular and survival effects of sympatho-inhibitors in adriamycin-induced cardiomyopathy in rats. Fundam Clin Pharmacol 18:649-655.
50. Torrado M, Nespereira B, Bouzamayor Y, Centeno A, Lopez E, Mikhailov AT. 2006. Differential atrial versus ventricular ANKRD1 gene expression is oppositely regulated at diastolic heart failure. FEBS Lett 580:4182-4187.
51. Villani F, Meazza R, Materazzo C. 2006. Non-invasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: comparison with echocardiography. Anticancer Res 26:797-801.
52. Watson LE, Sheth M, Denyer RF, Dostal DE. 2004. Baseline echocardiographic values for adult male rats. J Am Soc Echocardiogr 17:161-167.
53. Wondergem J, Franken NA, Chin A, van Ravels FJ, Leer JW. 1998. Additive effect of concomitant multiple low-dose doxorubicin and thoracic irradiation on ex vivo cardiac performance of the rat heart. J Cancer Res Clin Oncol 124:148-154.
54. Wu HY, Kang YJ. 1998. Inhibition of buthionine sulfoximine-enhanced doxorubicin toxicity in metallothionein overexpressing transgenic mouse heart. J Pharmacol Exp Ther 287:515-520.
55. Yagmurca M, Fadillioglu E, Erdogan H, Ucar M, Sogut S, Irmak MK. 2003. Erdosteine prevents doxorubicin-induced cardiotoxicity in rats. Pharmacol Res 48:377-382.
56. Yeung TK, Chakrabarti K, Wilding D, Hopewell JW. 2002. Modification of doxorubicin-induced cardiotoxicity: manipulation of the dosage schedule. Hum Exp Toxicol 21:607-614.
57. Yilmaz S, Atessahin A, Sahna E, Karahan I, Ozer S. 2006. Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity. Toxicology 218:164-171.